POINT RICHMOND, Calif., March 7, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, March 14, 2012 at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2011 financial results. The conference call will follow the release of the Transcept fourth quarter and full year 2011 financial results after the close of market that day.
(Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO)
Conference Call Information | |
| Date: Wednesday, March 14, 2012 |
| Time: 4:30 p.m. ET |
| Dial-in (U.S.): 877-638-4558 |
| Dial-in (International): 914-495-8537 |
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through May 31, 2012.
A telephone replay of the conference call will be available shortly after the conclusion of the call through March 19, 2012. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 50417502.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com.
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
